Loading
Statistician who invented the multi-arm multi-stage design behind STAMPEDE, letting one trial test many treatments at once.
Mahesh Parmar developed the multi-arm multi-stage (MAMS) platform trial design and applied it in STAMPEDE, which tested ten treatment approaches for advanced prostate cancer in a single trial and established docetaxel and abiraterone as standards. He directs the MRC Clinical Trials Unit at UCL, which runs trials across cancer, HIV and tuberculosis, and has led methodological work on adaptive designs and meta-analysis.
| Title | Journal | Year |
|---|---|---|
| Speeding up the evaluation of new agents in cancer | JNCI | 2008 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol | Annals of Oncology | 2018 |
| STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer | New England Journal of Medicine | 2017 |
Shares STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, Master protocol (platform, basket and umbrella trials), STAMPEDE, University College London Hospitals / UCL Cancer Institute.
Shares STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, STAMPEDE, Prostate cancer.
Shares STAMPEDE, University College London Hospitals / UCL Cancer Institute, Prostate cancer.
Shares STAMPEDE, Prostate cancer.
Shares STAMPEDE, Prostate cancer.
Shares STAMPEDE, University College London Hospitals / UCL Cancer Institute, Prostate cancer.
Shares STAMPEDE, Prostate cancer.
Shares University College London Hospitals / UCL Cancer Institute, Prostate cancer.